Afobazole

Afobazole
	File:Afobazole structure.png
Systematic (IUPAC) name
	5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole
Clinical data
Routes of; administration	Oral
Legal status
Legal status	℞ (Prescription only);
Identifiers
CAS Number	173352-39-1
ATC code	none
PubChem	CID 9862937
Chemical data
Formula	C15H21N3O2S
Molar mass	307.410 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Afobazole is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions, making it more selective in action than many currently used drugs for this application. Its mechanism of action remains poorly defined however, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism all thought to have some involvement.^[1]^[2]^[3]^[4]^[5] Clinical trials have shown afobazole to be well tolerated and reasonably effective for the treatment of anxiety, although it has yet to be introduced into widespread clinical use outside of Russia.^[6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

35px	This drug article relating to the nervous system is a stub. You can help ssf by expanding it. v d e

This medical article is a stub. You can help ssf by expanding it.

↑ Neznamov GG, Siuniakov SA, Chumakov DV, Bochkarev VK, Seredenin SB. Clinical study of the selective anxiolytic agent afobazol. Eksp Klin Farmakol. 2001 Mar-Apr;64(2):15-9. Russian. PMID 11548440
↑ Silkina IV, Gan'shina TC, Seredin SB, Mirzoian RS. Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. Eksp Klin Farmakol. 2005 Jan-Feb;68(1):20-4. Russian. PMID 15786959
↑ Seredin SB, Melkumian DS, Val'dman EA, Iarkova MA, Seredina TC, Voronin MV, Lapitskaia AS. Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction. Eksp Klin Farmakol. 2006 May-Jun;69(3):3-6. Russian. PMID 16878488
↑ Antipova TA, Sapozhnikova DS, Bakhtina LIu, Seredenin SB. Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons. Eksp Klin Farmakol. 2009 Jan-Feb;72(1):12-4. Russian. PMID 19334503
↑ Seredenin SB, Antipova TA, Voronin MV, Kurchashova SY, Kuimov AN. Interaction of Afobazole with sigma(1)-Receptors. Bull Exp Biol Med. 2009 Jul;148(1):42-4. English, Russian. PMID 19902093
↑ Medvedev VE, Trosnova AP, Dobrovol'skiĭ AV. Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole. Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(7):25-9. Russian. PMID 18379478

[1] Neznamov GG, Siuniakov SA, Chumakov DV, Bochkarev VK, Seredenin SB. Clinical study of the selective anxiolytic agent afobazol. Eksp Klin Farmakol. 2001 Mar-Apr;64(2):15-9. Russian. PMID 11548440

[2] Silkina IV, Gan'shina TC, Seredin SB, Mirzoian RS. Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. Eksp Klin Farmakol. 2005 Jan-Feb;68(1):20-4. Russian. PMID 15786959

[3] Seredin SB, Melkumian DS, Val'dman EA, Iarkova MA, Seredina TC, Voronin MV, Lapitskaia AS. Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction. Eksp Klin Farmakol. 2006 May-Jun;69(3):3-6. Russian. PMID 16878488

[4] Antipova TA, Sapozhnikova DS, Bakhtina LIu, Seredenin SB. Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons. Eksp Klin Farmakol. 2009 Jan-Feb;72(1):12-4. Russian. PMID 19334503

[5] Seredenin SB, Antipova TA, Voronin MV, Kurchashova SY, Kuimov AN. Interaction of Afobazole with sigma(1)-Receptors. Bull Exp Biol Med. 2009 Jul;148(1):42-4. English, Russian. PMID 19902093

[6] Medvedev VE, Trosnova AP, Dobrovol'skiĭ AV. Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole. Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(7):25-9. Russian. PMID 18379478

[1]

[2]

[3]

[4]

[5]

[6]

v t e Sigma receptor modulators
Agonists	3-MeO-PCE 3-MeO-PCP 3-PPP 4-MeO-PCP 4-IBP 4-PPBP Afobazole Alazocine Amantadine Amitriptyline Arketamine BD-1008 BD1031 BD1052 Berberine Buprenorphine Captodiame Citalopram Clorgiline Cocaine Cutamesine Cyclazocine DHEA DHEA-S Desipramine Dextrallorphan Dextromethorphan Dextrorphan Dimemorfan DMT Donepezil DTG Escitalopram Fluoxetine Fluvoxamine Heroin Ibogaine Igmesine Imipramine JO-1784 Ketamine L-687,384 Lamotrigine Lu 28-179 MDMA Memantine Metaphit Methamphetamine Methoxetamine Methylphenidate Morphine Naluzotan Noscapine OPC-14523 Opipramol PB-28 PD-144,415 Pentazocine Pentoxyverine Phencyclidine PRE-084 Pregnenolone Pregnenolone sulfate Quetiapine RTI-55 SA-4503 Siramesine Tapentadol Tenocyclidine Tramadol UMB23 UMB82 Venlafaxine
Antagonists	AC927 AHD1 AZ66 BD1008 BD1047 BD1060 BD1063 BD1067 BMY-14802 CM156 E-5842 Haloperidol Lamotrigine LR132 LR172 MIN-101 MS-377 Naloxone Naltrexone NE-100 Panamesine PD-144418 Progesterone Quingestrone Rimcazole S1RA (E-52862) Sertraline SM-21 SR-31742A UMB100 UMB101 UMB103 UMB116 YZ-011 YZ-069 YZ-185
Unknown / unsorted	4C-T-2 5-MeO-DiPT 18-MC β-Endopsychosin Chlorpromazine Clemastine Clocapramine Cloperastine D-Deprenyl DiPT DPT Gevotroline Nepinalone Selegiline TMA; Allosteric modulators: SKF-83959

Afobazole

References

Navigation menu

Views

Personal tools

Navigation

Search

Tools

adverts